Accelerate Diagnostics Inc (AXDX) : Oaktop Capital Management Ii added new position in Accelerate Diagnostics Inc during the most recent quarter end. The investment management firm now holds 125,000 shares of Accelerate Diagnostics Inc which is valued at $2,621,250 , the company said in a statement filed on Aug 9, 2016 with the SEC.Accelerate Diagnostics Inc makes up approximately 0.57% of Oaktop Capital Management Ii’s portfolio.
Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in AXDX in the latest quarter, The investment management firm added 517 additional shares and now holds a total of 4,222 shares of Accelerate Diagnostics Inc which is valued at $88,535.State Board Of Administration Of Florida Retirement System boosted its stake in AXDX in the latest quarter, The investment management firm added 1,580 additional shares and now holds a total of 15,898 shares of Accelerate Diagnostics Inc which is valued at $334,971.Swiss National Bank boosted its stake in AXDX in the latest quarter, The investment management firm added 1,400 additional shares and now holds a total of 54,100 shares of Accelerate Diagnostics Inc which is valued at $1,108,509. Stoneridge Investment Partners sold out all of its stake in AXDX during the most recent quarter. The investment firm sold 23,328 shares of AXDX which is valued $465,627.
Accelerate Diagnostics Inc opened for trading at $22.45 and hit $23.5332 on the upside on Wednesday, eventually ending the session at $22.33, with a gain of 0.22% or 0.05 points. The heightened volatility saw the trading volume jump to 9,59,246 shares. Company has a market cap of $1,144 M.
Accelerate Diagnostics Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform the Accelerate ID/AST System (the ID/AST System) intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST) which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.